Core Insights - Science Corporation, a U.S. neurotechnology company, completed a $230 million Series C funding round, bringing its total funding to nearly $490 million since its establishment in 2021 [2] - The company focuses on a visual restoration implant device rather than a traditional brain-computer interface (BCI), positioning itself to potentially be one of the first BCI companies to achieve commercialization [2] - This funding indicates a shift in investor interest towards commercially viable applications within the neurotechnology sector [2] Company Overview - Founded in 2021 and headquartered in Alameda, California, Science Corp was co-founded by Max Hodak, a notable figure from Neuralink [3] - The company acquired key technology through the purchase of assets from French visual neurointerface company Pixium Vision, gaining the PRIMA retinal implant system [3] Technology and Product Details - The PRIMA system consists of three components: a camera that captures images, a microchip implanted under the retina that stimulates retinal nerve signals, and a processing system [4][6] - This system operates at the retinal level rather than directly in the brain, which may facilitate regulatory approval and enhance safety [5] - The PRIMA system has received FDA Breakthrough Device designation and is pursuing CE certification in Europe [5] Market Trends - The BCI industry has seen a notable increase in funding over the past two years, with a trend shifting from conceptual BCI to clinically viable products [17] - Science Corp's funding will primarily support the commercialization of the PRIMA system and the development of its next-generation Biohybrid neural interface technology [18] - Other companies in the sector, such as Neuralink and Paradromics, have also secured significant funding, indicating a growing interest in neurotechnology [20] Implications for the Chinese Market - The BCI sector in China is rapidly developing, with several companies emerging in areas like brain signal acquisition and neuroregulation [22][23] - However, most Chinese BCI companies are still in the research or early clinical stages, with few products ready for large-scale medical application [24] - Science Corp's approach of targeting specific diseases rather than pursuing a general BCI could serve as a valuable model for Chinese companies [25]